AU2018349259B2 - Crystalline form of lorlatinib free base hydrate - Google Patents

Crystalline form of lorlatinib free base hydrate Download PDF

Info

Publication number
AU2018349259B2
AU2018349259B2 AU2018349259A AU2018349259A AU2018349259B2 AU 2018349259 B2 AU2018349259 B2 AU 2018349259B2 AU 2018349259 A AU2018349259 A AU 2018349259A AU 2018349259 A AU2018349259 A AU 2018349259A AU 2018349259 B2 AU2018349259 B2 AU 2018349259B2
Authority
AU
Australia
Prior art keywords
ppm
free base
crystalline form
cancer
base hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018349259A
Other languages
English (en)
Other versions
AU2018349259A1 (en
Inventor
Paul Bowles
Peter Robert Rose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64049474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018349259(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU2018349259A1 publication Critical patent/AU2018349259A1/en
Application granted granted Critical
Publication of AU2018349259B2 publication Critical patent/AU2018349259B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2018349259A 2017-10-10 2018-10-04 Crystalline form of lorlatinib free base hydrate Active AU2018349259B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762570326P 2017-10-10 2017-10-10
US62/570,326 2017-10-10
US201862727734P 2018-09-06 2018-09-06
US62/727,734 2018-09-06
PCT/IB2018/057735 WO2019073347A1 (en) 2017-10-10 2018-10-04 CRYSTALLINE BASE FREE HYDRATE SHAPE OF LORLATINIB

Publications (2)

Publication Number Publication Date
AU2018349259A1 AU2018349259A1 (en) 2020-04-09
AU2018349259B2 true AU2018349259B2 (en) 2021-02-18

Family

ID=64049474

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018349259A Active AU2018349259B2 (en) 2017-10-10 2018-10-04 Crystalline form of lorlatinib free base hydrate

Country Status (21)

Country Link
US (1) US11299500B2 (enExample)
EP (1) EP3694863B1 (enExample)
JP (1) JP7153069B2 (enExample)
KR (1) KR102424621B1 (enExample)
CN (1) CN111201235B (enExample)
AU (1) AU2018349259B2 (enExample)
CA (1) CA3077508C (enExample)
CY (1) CY1126141T1 (enExample)
DK (1) DK3694863T3 (enExample)
ES (1) ES2952985T3 (enExample)
FI (1) FI3694863T3 (enExample)
HU (1) HUE062926T2 (enExample)
MX (1) MX2020003373A (enExample)
PL (1) PL3694863T3 (enExample)
PT (1) PT3694863T (enExample)
RU (1) RU2022109286A (enExample)
SG (1) SG11202002445SA (enExample)
SI (1) SI3694863T1 (enExample)
TW (1) TWI775960B (enExample)
WO (1) WO2019073347A1 (enExample)
ZA (1) ZA202001661B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913200XA (en) 2015-07-31 2020-03-30 Pfizer Crystalline form of lorlatinib free base
CA3019905C (en) 2016-04-08 2022-08-23 Pfizer Inc. Crystalline forms of lorlatinib maleate
WO2019209633A1 (en) * 2018-04-23 2019-10-31 Pliva Hrvatska D.O.O. Solid state forms of lorlatinib and their preparation
US12391708B2 (en) 2019-07-18 2025-08-19 Tapi Croatia Industries Ltd Crystalline Lorlatinib : fumaric acid and solid state form thereof
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
EP4041396A1 (en) 2019-10-10 2022-08-17 Sandoz AG Polymorph of lorlatinib
CN112824417A (zh) * 2019-11-21 2021-05-21 上海天慈国际药业有限公司 一种劳拉替尼的制备方法
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
CN111362967B (zh) * 2020-04-28 2021-09-07 南京雷正医药科技有限公司 苯并氧杂二氮杂十四碳烯衍生物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014207606A1 (en) * 2013-06-28 2014-12-31 Pfizer Inc. Solid forms of a macrocyclic kinase inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2796967C (en) 2010-05-04 2015-12-01 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
PE20141639A1 (es) * 2011-06-08 2014-11-08 Biogen Idec Inc Proceso para preparar fumarato de dimetilo de alta pureza y cristalino
CA2863892C (en) * 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
EP3183256A4 (en) * 2014-08-20 2018-05-30 Teligene Ltd. Substituted macrocycles useful as kinases inhibitors and methods of use thereof
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
SG10201913200XA (en) 2015-07-31 2020-03-30 Pfizer Crystalline form of lorlatinib free base
CA3019905C (en) 2016-04-08 2022-08-23 Pfizer Inc. Crystalline forms of lorlatinib maleate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014207606A1 (en) * 2013-06-28 2014-12-31 Pfizer Inc. Solid forms of a macrocyclic kinase inhibitor

Also Published As

Publication number Publication date
PL3694863T3 (pl) 2023-09-25
TWI775960B (zh) 2022-09-01
AU2018349259A1 (en) 2020-04-09
JP7153069B2 (ja) 2022-10-13
DK3694863T3 (da) 2023-07-03
EP3694863A1 (en) 2020-08-19
TW201922753A (zh) 2019-06-16
CN111201235B (zh) 2023-02-10
WO2019073347A1 (en) 2019-04-18
US11299500B2 (en) 2022-04-12
HUE062926T2 (hu) 2023-12-28
SG11202002445SA (en) 2020-04-29
RU2020113141A (ru) 2021-11-12
PT3694863T (pt) 2023-08-23
EP3694863B1 (en) 2023-06-21
JP2020536893A (ja) 2020-12-17
ES2952985T3 (es) 2023-11-07
KR20200051781A (ko) 2020-05-13
ZA202001661B (en) 2023-11-29
MX2020003373A (es) 2020-10-12
US20200308191A1 (en) 2020-10-01
CA3077508A1 (en) 2019-04-18
BR112020005989A2 (pt) 2020-09-29
CA3077508C (en) 2023-02-14
CY1126141T1 (el) 2023-11-15
RU2020113141A3 (enExample) 2021-11-12
CN111201235A (zh) 2020-05-26
FI3694863T3 (fi) 2023-08-18
RU2022109286A (ru) 2022-05-06
SI3694863T1 (sl) 2023-10-30
KR102424621B1 (ko) 2022-07-25

Similar Documents

Publication Publication Date Title
CA3077508C (en) Crystalline form of lorlatinib free base hydrate
US11020376B2 (en) Crystalline form of lorlatinib free base
CA3019905C (en) Crystalline forms of lorlatinib maleate
RU2845218C2 (ru) Кристаллическая форма гидрата свободного основания лорлатиниба
HK40029499B (en) Crystalline form of lorlatinib free base hydrate
HK40029499A (en) Crystalline form of lorlatinib free base hydrate
BR112020005989B1 (pt) Forma cristalina de hidrato de base livre de lorlatinibe, composição e usos
TW202328152A (zh) 氮雜內醯胺化合物之晶型

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)